This review highlights the clinical challenge of aspirin resistance and emphasizes the potential need for monitoring to customize antiplatelet therapy in at-risk patients.
Answers are grounded in this paper and cite their sources.
Caution against routine aspirin resistance monitoring; leaves open whether customized antiplatelet strategies improve outcomes.
Platelets play a very important role in the pathogenesis of acute vascular events leading to thrombosis of the coronary and cerebral arteries. Blockage of these arteries leading to regional ischemia of heart and brain tissues precipitate heart attacks and stroke. Acetyl salicylic acid (Aspirin) has been the drug of choice for over half a century for the primary and secondary prophylaxis of thrombotic events. In spite of its extensive use as an antiplatelet drug for the prevention of vascular thrombosis, there is considerable concern about the degree of protection it offers, to patients under aspirin therapy. In this paper, we explain the phenomenon of aspirin resistance, discuss the limitations of aspirin therapy, and suggest methods to monitor "at-risk" individuals. Ability to monitor and determine at risk patients will provide opportunities for the clinicians to customize antiplatelet therapies.
No takes yet. Share an insight, caveat, or question.
Rao et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: